Literature DB >> 11960312

Pegylated GL67 lipoplexes retain their gene transfection activity after exposure to components of CF mucus.

N N Sanders1, S C De Smedt, S H Cheng, J Demeester.   

Abstract

The highly viscous secretions lining the upper airways and bronchi of cystic fibrosis (CF) patients may pose a significant barrier to successful gene therapy of the lung. In this report we examined the influence of CF mucus components (albumin, DNA, mucin and phospholipids) on the gene transfection activity of cationic DOTAP-based lipoplexes and pegylated GL67-based lipoplexes which previously have been used in CF clinical studies. Upon exposure of the cationic DOTAP:DOPE lipoplexes to either albumin, linear DNA or mucin (at concentration ratios expected to occur in vivo) a significant decrease in gene transfection activity was observed. This was primarily due to aggregation of the lipoplexes. However, exposure of pegylated GL67 lipoplexes to the same components did not affect their gene transfection activity. Indeed, it was determined that CF mucus components did not interact significantly with these pegylated GL67 lipoplexes. These results suggest that charge shielding of cationic gene carriers with pEG may favor their physicochemical stability in CF mucus and thereby aid in preserving their transfection activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11960312     DOI: 10.1038/sj.gt.3301663

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  13 in total

1.  Three-dimensional fluorescence recovery after photobleaching with the confocal scanning laser microscope.

Authors:  Kevin Braeckmans; Liesbeth Peeters; Niek N Sanders; Stefaan C De Smedt; Joseph Demeester
Journal:  Biophys J       Date:  2003-10       Impact factor: 4.033

Review 2.  Materials engineering for immunomodulation.

Authors:  Jeffrey A Hubbell; Susan N Thomas; Melody A Swartz
Journal:  Nature       Date:  2009-11-26       Impact factor: 49.962

Review 3.  The importance of the vaginal delivery route for antiretrovirals in HIV prevention.

Authors:  Lindsay M Ferguson; Lisa Cencia Rohan
Journal:  Ther Deliv       Date:  2011-12

Review 4.  Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases.

Authors:  Itishri Sahu; A K M Ashiqul Haque; Brian Weidensee; Petra Weinmann; Michael S D Kormann
Journal:  Mol Ther       Date:  2019-03-06       Impact factor: 11.454

Review 5.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

Review 6.  Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.

Authors:  Jaleh Varshosaz; Maryam Farzan
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 7.  Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery.

Authors:  Laura M Ensign; Craig Schneider; Jung Soo Suk; Richard Cone; Justin Hanes
Journal:  Adv Mater       Date:  2012-07-24       Impact factor: 30.849

Review 8.  Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.

Authors:  Samuel K Lai; Ying-Ying Wang; Justin Hanes
Journal:  Adv Drug Deliv Rev       Date:  2008-12-13       Impact factor: 15.470

9.  PEGylation of nanoparticles improves their cytoplasmic transport.

Authors:  Junghae Suh; Kok-Leong Choy; Samuel K Lai; Jung Soo Suk; Benjamin C Tang; Sudhir Prabhu; Justin Hanes
Journal:  Int J Nanomedicine       Date:  2007

10.  Targeting of Synthetic Gene Delivery Systems.

Authors:  Andreas G. Schätzlein
Journal:  J Biomed Biotechnol       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.